A Phase 2 Platform Study of Immunomodulatory Compounds in ICI-refractory Non-small Cell Lung Cancer

NCT07133425 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

29

Enrollment

OTHER

Sponsor class

Conditions

Non-Small Cell Lung Cancer
ICI-refractory

Interventions

DRUG: SAR445877

Sponsor

M.D. Anderson Cancer Center

Collaborators

[object Object]